A locally developed Covid-19 treatment drug called Vipdervir will be tested on 260 Covid-19 patients.
The Vietnamese Academy of Science and Technology has announced the results of preclinical research on a Covid-19 treatment drug called Vipdervir, which is made entirely from Vietnamese herbs. The project is chaired by Assoc. Professor Dr Le Quang Huan, Principal Investigator at the Institute of Biotechnology, Vietnam Academy of Science and Technology.
The National Council of Ethics for Biomedical Research, Ministry of Health, welcomed the results of preclinical studies and approved the clinical trial of Vipdervir in patients with Covid-19.
The Ministry of Health will coordinate with the Vietnam Academy of Science and Technology to request relevant agencies to conduct clinical trials on 260 Covid-19 patients. If the results of the clinical trial are safe and effective, the Administration of Traditional Medicine and Pharmacy will consider authorizing the drug.
Dr Nguyen Ngo Quang, deputy director of the Department of Scientific and Technological Training, Ministry of Health, says that the advantage of the clinical trial process is that the number of Covid-19 patients, especially those with mild symptoms and moderate, is very important. , recruiting volunteers to participate in the study is therefore practical. Secondly, Vipdervir is made entirely of herbs, which is a product of traditional medicine, so many people want to use it.
The clinical research period is scheduled for around 2 to 3 months, then an additional 1 to 2 months is needed for scientists to summarize the research.
“We hope that this product will be approved by the end of this year,” said Dr Nguyen Ngo Quang.
The results of preclinical studies show that Vipdervir is safe and effective in inhibiting the growth of the SARS-CoV-2 virus, enhancing immunity in experimental models.
According to Dr Le Quang Huan, the research team used bioinformatics technology to screen for the main active ingredients of herbs with high binding affinity to molecules involved in the invasion and proliferation of the SARS-CoV-2 virus. They also combined old and modern medical documents and recent international publications to create a product with the highest treatment efficiency.
Based on this, Vipdervir can prevent virus adhesion to the host cell, and inhibit viral replication while activating immune cells to recognize, block and eliminate virus particles. These mechanisms have a synergistic effect to help prevent and treat Covid-19.
In a preclinical study in rabbits, after administering to rabbits an oral suspension with two doses of 0.378 tablets / kg rabbit / day for 28 consecutive days (equivalent to the maximum human dose of 6 tablets / person / day) and 1.133 tablets / kg rabbit / day (3 times the maximum human dose), the test sample did not affect the weight, body condition and movements of the rabbits.
The rabbits were healthy with no difference in weight before, between and after the test.
The toxicity of Vipdervir has been evaluated at the Faculty of Pharmacology, Hanoi University of Medicine and at the Central Institute for Drug Testing. It was evaluated for its ability to inhibit the H5N1 virus at the Institute of Biotechnology and evaluated for its ability to inhibit the SARS-CoV-2 virus at the Central Institute of Hygiene and Epidemiology.
Remdesivir approved for COVID-19 treatment in Vietnam
The first 50,000 vials of Remdesivir from India arrived at Tan Son Nhat airport in Ho Chi Minh City on Thursday August 5th and another 40,000 vials arrived on Friday evening.
Traditional medicine used to treat patients with Covid-19
The Ministry of Health (MOH) has authorized the use of xuyen tam lien (Andrographis paniculata), a familiar traditional medicine, in the treatment of Covid-19, according to Luong Ngoc Khe, director of the administration of medical examinations and treatments .